What is the official website of Hikma Pharmaceuticals ?

The official website of Hikma Pharmaceuticals is http://www.hikma.com.

What is Hikma Pharmaceuticals's cybersecurity risk score?

Hikma Pharmaceuticals has an AI-generated cybersecurity risk score of 767 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Hikma Pharmaceuticals experienced?

According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Hikma Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Hikma Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.

Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Hikma Pharmaceuticals comply with GDPR ?

According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.

Does Hikma Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Hikma Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.

Does Hikma Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Hikma Pharmaceuticals operate in ?

Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals employs approximately 10,252 people worldwide.

Does Hikma Pharmaceuticals own any subsidiaries ?

Hikma Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals's official LinkedIn profile has approximately 637,630 followers.

What is the NAICS classification code for Hikma Pharmaceuticals ?

Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Hikma Pharmaceuticals have a Crunchbase profile ?

Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.

Does Hikma Pharmaceuticals have a LinkedIn profile ?

Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.

How many cybersecurity incidents has Hikma Pharmaceuticals experienced ?

As of June 12, 2026, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals has an estimated 5,685 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Hikma Pharmaceuticals

Boost Score +25 with badge (5 left)

767

/1000

Fair

792

/1000

Fair

Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score

hikma.com

cb in

Add Your Compliance Badge

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Hikma Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Hikma Pharmaceuticals

Hikma Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.hikma.com

Company Size: 5,001-10,000 employees

No subsidiary data available for this company.

Loading…

Hikma Pharmaceuticals Similar Companies

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Loading…

NEWS

Hikma Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2026 08:00 AM

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has put fresh attention...

Read Article

February 26, 2026 08:00 AM

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

British generic drugmaker Hikma Pharmaceuticals scrapped its medium-term targets as it forecast slower annual revenue growth and profit on...

Read Article

February 06, 2026 08:00 AM

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions...

Read Article

January 08, 2026 08:00 AM

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

Hikma Pharmaceuticals' fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the...

Read Article

December 16, 2025 08:00 AM

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

Directors Nina Henderson and John Zangardi on the key differences between serving on multinational and domestic boards.

Read Article

December 15, 2025 08:00 AM

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

Hikma Pharmaceuticals' latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts...

Read Article

November 28, 2025 08:00 AM

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share.

Read Article

November 13, 2025 08:00 AM

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light...

Read Article

September 19, 2025 07:00 AM

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-47238

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #133, a normal authenticated user can edit another user's video subtitles because of a lack of authorization. They can upload subtitles, edit their name or delete them. This issue has been patched in version 5.5.3 - #133.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

Impact Score

2.5

Exploitability

3.9

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-x468-whmw-c863

CVE-2026-45418

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #132, any authenticated user who can upload videos can add multiple subtitles from different files and change their title (English, Spanish...). The POST /actions/subtitle_edit.php request used to change their title includes a number parameter which is vulnerable to SQL Injection. A boolean-based blind SQL injection can be used to exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #132.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-q233-m544-6jqr

CVE-2026-45060

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #129, the actions/progress_video.php endpoint is vulnerable to blind SQL injection. Any unauthenticated user can exploit the ids parameter to execute SQL queries and exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #129.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-wpq3-gxx7-c76h

CVE-2026-42846

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #140, ClipBucket's Remote Play feature allows any authenticated user to add a video by importing an external URL as the source. Some shell commands are run with the URL as a parameter. The URL is concatenated directly into shell commands without escaping then executed, so any shell metacharacter in the URL is interpreted. This results in arbitrary command execution. This issue has been patched in version 5.5.3 - #140.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-hvfx-hxmr-28c7

CVE-2026-6250

SUMMARY

An authenticated format string vulnerability exists in the ONVIF service of Tapo C110 v2 due to improper handling of user-controlled input. Externally controlled data is interpreted as a format string, which can be used to manipulate stack memory, including control flow data such as return addresses. A remote authenticated attacker may redirect execution flow to existing internal functions, triggering an unauthorized factory reset, leading to loss of configuration, deletion of stored credentials and service disruption.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: )

cvss4

Base Score: 7.0

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:L/UI:N/VC:N/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…